person · Reporting owner

BUTITTA CYNTHIA M

Disclosed activity across 5 companies

Tapewire entity: 33881
SEC CIK: 0001222082

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
Autolus Therapeutics plcAUTL · Entity 1933	Director	June 29, 2026	July 01, 2026
Century Therapeutics, Inc.IPSC · Entity 5739	Director	June 12, 2025	June 16, 2025
Olema Pharmaceuticals, Inc.OLMA · Entity 613	Director	June 18, 2026	June 23, 2026
UroGen Pharma Ltd.URGN · Entity 4466	Director	June 22, 2026	June 24, 2026

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Autolus Therapeutics plc

Report date June 29, 2026 · Filed July 01, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Restricted Share UnitsSEC Table II · derivative / convertible security	Direct	31,667	Reported balance After 2026-06-29 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2026-06-29 · Grant · Acquired 31,667 · Balance 31,667 F1: Each restricted stock unit (RSU) represents a contingent right to receive one share of the Issuer's American Depositary Shares. Each American Depositary Share is convertible at any time at the option of the Reporting Person into one Ordinary Share. F2: The RSUs vest in one installment on June 29, 2027.
Share Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.61 · Expires 2036-06-29	Direct	47,500	Reported balance After 2026-06-29 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2026-06-29 · Grant · Acquired 47,500 · Balance 47,500 F3: Share options vest in twelve equal monthly installments commencing on July 29, 2026.

Filing footnotes · ownership attribution and instrument terms

F1: Each restricted stock unit (RSU) represents a contingent right to receive one share of the Issuer's American Depositary Shares. Each American Depositary Share is convertible at any time at the option of the Reporting Person into one Ordinary Share.

F2: The RSUs vest in one installment on June 29, 2027.

F3: Share options vest in twelve equal monthly installments commencing on July 29, 2026.

Century Therapeutics, Inc.

Report date June 12, 2025 · Filed June 16, 2025

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.60 · Expires 2035-06-12	Direct	44,000	Reported balance After 2025-06-12 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2025-06-12 · Grant · Acquired 44,000 · Balance 44,000 F1: The option vests on the earlier of (a) June 12, 2026, or (b) the next annual meeting of stockholders, in each case subject to the Reporting Person's continued service through the applicable vesting date.

Filing footnotes · ownership attribution and instrument terms

F1: The option vests on the earlier of (a) June 12, 2026, or (b) the next annual meeting of stockholders, in each case subject to the Reporting Person's continued service through the applicable vesting date.

Olema Pharmaceuticals, Inc.

Report date June 18, 2026 · Filed June 23, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $9.51 · Expires 2036-06-18	Direct	29,500	Reported balance After 2026-06-18 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2026-06-18 · Grant · Acquired 29,500 · Balance 29,500 F1: The shares subject to the option vest in a series of 12 successive equal monthly installments measured from June 18, 2026, subject to the Reporting Person's continuous service through each applicable vesting date. Such shares vest in full on the date of the Issuer's next annual meeting of stockholders if such stock option is not otherwise fully vested by such date, subject to the Reporting Person's continuous service through such vesting date.

Filing footnotes · ownership attribution and instrument terms

F1: The shares subject to the option vest in a series of 12 successive equal monthly installments measured from June 18, 2026, subject to the Reporting Person's continuous service through each applicable vesting date. Such shares vest in full on the date of the Issuer's next annual meeting of stockholders if such stock option is not otherwise fully vested by such date, subject to the Reporting Person's continuous service through such vesting date.

UroGen Pharma Ltd.

Report date June 22, 2026 · Filed June 24, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Option (right ot buy)SEC Table II · derivative / convertible security · Conversion / exercise price $34.99 · Expires 2036-06-22	Direct	10,000	Reported balance After 2026-06-22 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2026-06-22 · Grant · Acquired 10,000 · Balance 10,000 F1: The shares underlying the stock option will vest in equal quarterly installments over a period of one year, subject to the director's Continuous Service (as defined in the 2017 Equity Incentive Plan) through such vesting dates.
Restricted Stock UnitSEC Table II · derivative / convertible security	Direct	8,000	Reported balance After 2026-06-22 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2026-06-22 · Grant · Acquired 8,000 · Balance 8,000 F2: Each restricted stock unit ("RSU") represents a contingent right to receive one ordinary share of the Issuer F3: The shares underlying the RSUs will vest in equal quarterly installments over a period of one year, subject to the director's Continuous Service (as defined in the 2017 Equity Incentive Plan) through such vesting dates.

Filing footnotes · ownership attribution and instrument terms

F1: The shares underlying the stock option will vest in equal quarterly installments over a period of one year, subject to the director's Continuous Service (as defined in the 2017 Equity Incentive Plan) through such vesting dates.

F2: Each restricted stock unit ("RSU") represents a contingent right to receive one ordinary share of the Issuer

F3: The shares underlying the RSUs will vest in equal quarterly installments over a period of one year, subject to the director's Continuous Service (as defined in the 2017 Equity Incentive Plan) through such vesting dates.

Past disclosures · reporting ended (1)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

Kite Pharma, Inc.

Report date October 03, 2017 · Filed October 06, 2017

Section 16 reporting ended · disclosed 2017-10-06. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Common StockSEC Table I · non-derivative	Direct	Ending reported balance After 2017-10-03 transaction · row 2 2 source rows · reconciled sequence Row 1 · 2017-09-21 · Gift · Disposed 27,900 · Balance 93,667 Row 2 · 2017-10-03 · Disposition to issuer · Disposed 93,667 · Balance 0 F1: On August 27, 2017, Kite Pharma, Inc., a Delaware corporation (the "Company"), entered into an Agreement and Plan of Merger (the "Merger Agreement") with Gilead Sciences, Inc., a Delaware corporation ("Parent"), and Dodgers Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Purchaser"). On October 3, 2017, Purchaser merged with and into the Company pursuant to Section 251(h) of the General Corporation Law of the State of Delaware, with the Company being the surviving corporation (the "Merger") and becoming a wholly-owned subsidiary of Parent. F2: Pursuant to the terms of the Merger Agreement and the Offer (as defined in the Merger Agreement), each share of Company common stock held by the Reporting Person, other than the shares described in Notes 3 and 4 below, was converted into the right to receive an amount in cash equal to $180.00 (the "per-share merger consideration"), without interest and subject to any required withholding of taxes. F3: Includes 38,675 shares of Company common stock underlying restricted stock units with respect to Company common stock, including all time-vesting and all performance-vesting restricted stock units (each a "Company Restricted Stock Unit"), held by the Reporting Person. F4: Pursuant to the terms of the Merger Agreement, each Company Restricted Stock Unit was assumed and converted into a restricted stock unit denominated in shares of Parent common stock, on the same terms and conditions as were then applicable under such Company Restricted Stock Unit (including applicable performance vesting conditions), and relating to a number of shares of Parent common stock equal to the product of (i) the total number of shares of Company common stock subject to such Company Restricted Stock Unit multiplied by (ii) the quotient of (A) $180.00 divided by (B) the volume-weighted average closing sale price of a share of Parent common stock for the fifteen full consecutive trading days ending on and including September 28, 2017 ($83.12) (such quotient, the "Equity Award Conversion Ratio").
Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.35 · Expires 2024-03-24	Direct	Reported balance After 2017-10-03 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2017-10-03 · Disposition to issuer · Disposed 44,110 · Balance 0 F1: On August 27, 2017, Kite Pharma, Inc., a Delaware corporation (the "Company"), entered into an Agreement and Plan of Merger (the "Merger Agreement") with Gilead Sciences, Inc., a Delaware corporation ("Parent"), and Dodgers Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Purchaser"). On October 3, 2017, Purchaser merged with and into the Company pursuant to Section 251(h) of the General Corporation Law of the State of Delaware, with the Company being the surviving corporation (the "Merger") and becoming a wholly-owned subsidiary of Parent. F6: This vested option was cancelled at the effective time of the Merger in exchange for a cash payment equal to the per-share merger consideration, less the exercise price of the option. F5: This option provided for vesting as to 108,839 shares on December 15, 2017 and vesting as to 9,071 shares per month thereafter.
Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.35 · Expires 2024-03-24	Direct	Reported balance After 2017-10-03 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2017-10-03 · Disposition to issuer · Disposed 36,284 · Balance 0 F1: On August 27, 2017, Kite Pharma, Inc., a Delaware corporation (the "Company"), entered into an Agreement and Plan of Merger (the "Merger Agreement") with Gilead Sciences, Inc., a Delaware corporation ("Parent"), and Dodgers Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Purchaser"). On October 3, 2017, Purchaser merged with and into the Company pursuant to Section 251(h) of the General Corporation Law of the State of Delaware, with the Company being the surviving corporation (the "Merger") and becoming a wholly-owned subsidiary of Parent. F7: Pursuant to the terms of the Merger Agreement, each option to purchase Company common stock (each, a "Company Option") then outstanding and unexercised, other than any vested in-the-money Company Option, was assumed and converted into an option to purchase a number of shares of Parent common stock, on the same terms and subject to the same conditions as were applicable to such Company Option, equal to the product of (i) the total number of shares of Company common stock subject to such Company Option multiplied by (ii) the Equity Award Conversion Ratio, and with an exercise price equal to the quotient of (i) the exercise price of such Company Option divided by (ii) the Equity Award Conversion Ratio. F5: This option provided for vesting as to 108,839 shares on December 15, 2017 and vesting as to 9,071 shares per month thereafter.
Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $17.00 · Expires 2024-06-19	Direct	Reported balance After 2017-10-03 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2017-10-03 · Disposition to issuer · Disposed 121,477 · Balance 0 F1: On August 27, 2017, Kite Pharma, Inc., a Delaware corporation (the "Company"), entered into an Agreement and Plan of Merger (the "Merger Agreement") with Gilead Sciences, Inc., a Delaware corporation ("Parent"), and Dodgers Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Purchaser"). On October 3, 2017, Purchaser merged with and into the Company pursuant to Section 251(h) of the General Corporation Law of the State of Delaware, with the Company being the surviving corporation (the "Merger") and becoming a wholly-owned subsidiary of Parent. F6: This vested option was cancelled at the effective time of the Merger in exchange for a cash payment equal to the per-share merger consideration, less the exercise price of the option. F8: This option provided for 25% vesting on June 20, 2015, and vesting thereafter in 36 equal monthly installments.
Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $17.00 · Expires 2024-06-19	Direct	Reported balance After 2017-10-03 transaction · row 6 Instrument identity requires review; Table II rows are not merged. 1 source row Row 6 · 2017-10-03 · Disposition to issuer · Disposed 28,034 · Balance 0 F1: On August 27, 2017, Kite Pharma, Inc., a Delaware corporation (the "Company"), entered into an Agreement and Plan of Merger (the "Merger Agreement") with Gilead Sciences, Inc., a Delaware corporation ("Parent"), and Dodgers Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Purchaser"). On October 3, 2017, Purchaser merged with and into the Company pursuant to Section 251(h) of the General Corporation Law of the State of Delaware, with the Company being the surviving corporation (the "Merger") and becoming a wholly-owned subsidiary of Parent. F7: Pursuant to the terms of the Merger Agreement, each option to purchase Company common stock (each, a "Company Option") then outstanding and unexercised, other than any vested in-the-money Company Option, was assumed and converted into an option to purchase a number of shares of Parent common stock, on the same terms and subject to the same conditions as were applicable to such Company Option, equal to the product of (i) the total number of shares of Company common stock subject to such Company Option multiplied by (ii) the Equity Award Conversion Ratio, and with an exercise price equal to the quotient of (i) the exercise price of such Company Option divided by (ii) the Equity Award Conversion Ratio. F8: This option provided for 25% vesting on June 20, 2015, and vesting thereafter in 36 equal monthly installments.
Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $51.96 · Expires 2024-12-23	Direct	Reported balance After 2017-10-03 transaction · row 7 Instrument identity requires review; Table II rows are not merged. 1 source row Row 7 · 2017-10-03 · Disposition to issuer · Disposed 51,563 · Balance 0 F1: On August 27, 2017, Kite Pharma, Inc., a Delaware corporation (the "Company"), entered into an Agreement and Plan of Merger (the "Merger Agreement") with Gilead Sciences, Inc., a Delaware corporation ("Parent"), and Dodgers Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Purchaser"). On October 3, 2017, Purchaser merged with and into the Company pursuant to Section 251(h) of the General Corporation Law of the State of Delaware, with the Company being the surviving corporation (the "Merger") and becoming a wholly-owned subsidiary of Parent. F6: This vested option was cancelled at the effective time of the Merger in exchange for a cash payment equal to the per-share merger consideration, less the exercise price of the option. F9: This option provided for 25% vesting on December 24, 2015, and vesting thereafter in 36 equal monthly installments.
Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $51.96 · Expires 2024-12-23	Direct	Reported balance After 2017-10-03 transaction · row 8 Instrument identity requires review; Table II rows are not merged. 1 source row Row 8 · 2017-10-03 · Disposition to issuer · Disposed 23,437 · Balance 0 F1: On August 27, 2017, Kite Pharma, Inc., a Delaware corporation (the "Company"), entered into an Agreement and Plan of Merger (the "Merger Agreement") with Gilead Sciences, Inc., a Delaware corporation ("Parent"), and Dodgers Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Purchaser"). On October 3, 2017, Purchaser merged with and into the Company pursuant to Section 251(h) of the General Corporation Law of the State of Delaware, with the Company being the surviving corporation (the "Merger") and becoming a wholly-owned subsidiary of Parent. F7: Pursuant to the terms of the Merger Agreement, each option to purchase Company common stock (each, a "Company Option") then outstanding and unexercised, other than any vested in-the-money Company Option, was assumed and converted into an option to purchase a number of shares of Parent common stock, on the same terms and subject to the same conditions as were applicable to such Company Option, equal to the product of (i) the total number of shares of Company common stock subject to such Company Option multiplied by (ii) the Equity Award Conversion Ratio, and with an exercise price equal to the quotient of (i) the exercise price of such Company Option divided by (ii) the Equity Award Conversion Ratio. F9: This option provided for 25% vesting on December 24, 2015, and vesting thereafter in 36 equal monthly installments.
Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $63.87 · Expires 2025-12-16	Direct	Reported balance After 2017-10-03 transaction · row 9 Instrument identity requires review; Table II rows are not merged. 1 source row Row 9 · 2017-10-03 · Disposition to issuer · Disposed 28,919 · Balance 0 F1: On August 27, 2017, Kite Pharma, Inc., a Delaware corporation (the "Company"), entered into an Agreement and Plan of Merger (the "Merger Agreement") with Gilead Sciences, Inc., a Delaware corporation ("Parent"), and Dodgers Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Purchaser"). On October 3, 2017, Purchaser merged with and into the Company pursuant to Section 251(h) of the General Corporation Law of the State of Delaware, with the Company being the surviving corporation (the "Merger") and becoming a wholly-owned subsidiary of Parent. F6: This vested option was cancelled at the effective time of the Merger in exchange for a cash payment equal to the per-share merger consideration, less the exercise price of the option. F10: This option provided for 25% vesting on December 17, 2016, and vesting thereafter in 36 equal monthly installments.
Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $63.87 · Expires 2025-12-16	Direct	Reported balance After 2017-10-03 transaction · row 10 Instrument identity requires review; Table II rows are not merged. 1 source row Row 10 · 2017-10-03 · Disposition to issuer · Disposed 37,181 · Balance 0 F1: On August 27, 2017, Kite Pharma, Inc., a Delaware corporation (the "Company"), entered into an Agreement and Plan of Merger (the "Merger Agreement") with Gilead Sciences, Inc., a Delaware corporation ("Parent"), and Dodgers Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Purchaser"). On October 3, 2017, Purchaser merged with and into the Company pursuant to Section 251(h) of the General Corporation Law of the State of Delaware, with the Company being the surviving corporation (the "Merger") and becoming a wholly-owned subsidiary of Parent. F7: Pursuant to the terms of the Merger Agreement, each option to purchase Company common stock (each, a "Company Option") then outstanding and unexercised, other than any vested in-the-money Company Option, was assumed and converted into an option to purchase a number of shares of Parent common stock, on the same terms and subject to the same conditions as were applicable to such Company Option, equal to the product of (i) the total number of shares of Company common stock subject to such Company Option multiplied by (ii) the Equity Award Conversion Ratio, and with an exercise price equal to the quotient of (i) the exercise price of such Company Option divided by (ii) the Equity Award Conversion Ratio. F10: This option provided for 25% vesting on December 17, 2016, and vesting thereafter in 36 equal monthly installments.
Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $46.09 · Expires 2026-12-21	Direct	Reported balance After 2017-10-03 transaction · row 11 Instrument identity requires review; Table II rows are not merged. 1 source row Row 11 · 2017-10-03 · Disposition to issuer · Disposed 90,600 · Balance 0 F1: On August 27, 2017, Kite Pharma, Inc., a Delaware corporation (the "Company"), entered into an Agreement and Plan of Merger (the "Merger Agreement") with Gilead Sciences, Inc., a Delaware corporation ("Parent"), and Dodgers Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Purchaser"). On October 3, 2017, Purchaser merged with and into the Company pursuant to Section 251(h) of the General Corporation Law of the State of Delaware, with the Company being the surviving corporation (the "Merger") and becoming a wholly-owned subsidiary of Parent. F7: Pursuant to the terms of the Merger Agreement, each option to purchase Company common stock (each, a "Company Option") then outstanding and unexercised, other than any vested in-the-money Company Option, was assumed and converted into an option to purchase a number of shares of Parent common stock, on the same terms and subject to the same conditions as were applicable to such Company Option, equal to the product of (i) the total number of shares of Company common stock subject to such Company Option multiplied by (ii) the Equity Award Conversion Ratio, and with an exercise price equal to the quotient of (i) the exercise price of such Company Option divided by (ii) the Equity Award Conversion Ratio. F11: This option provides for 25% vesting on December 22, 2017, and vesting thereafter in 36 equal monthly installments.

Filing footnotes · ownership attribution and instrument terms

F1: On August 27, 2017, Kite Pharma, Inc., a Delaware corporation (the "Company"), entered into an Agreement and Plan of Merger (the "Merger Agreement") with Gilead Sciences, Inc., a Delaware corporation ("Parent"), and Dodgers Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Purchaser"). On October 3, 2017, Purchaser merged with and into the Company pursuant to Section 251(h) of the General Corporation Law of the State of Delaware, with the Company being the surviving corporation (the "Merger") and becoming a wholly-owned subsidiary of Parent.

F2: Pursuant to the terms of the Merger Agreement and the Offer (as defined in the Merger Agreement), each share of Company common stock held by the Reporting Person, other than the shares described in Notes 3 and 4 below, was converted into the right to receive an amount in cash equal to $180.00 (the "per-share merger consideration"), without interest and subject to any required withholding of taxes.

F3: Includes 38,675 shares of Company common stock underlying restricted stock units with respect to Company common stock, including all time-vesting and all performance-vesting restricted stock units (each a "Company Restricted Stock Unit"), held by the Reporting Person.

F4: Pursuant to the terms of the Merger Agreement, each Company Restricted Stock Unit was assumed and converted into a restricted stock unit denominated in shares of Parent common stock, on the same terms and conditions as were then applicable under such Company Restricted Stock Unit (including applicable performance vesting conditions), and relating to a number of shares of Parent common stock equal to the product of (i) the total number of shares of Company common stock subject to such Company Restricted Stock Unit multiplied by (ii) the quotient of (A) $180.00 divided by (B) the volume-weighted average closing sale price of a share of Parent common stock for the fifteen full consecutive trading days ending on and including September 28, 2017 ($83.12) (such quotient, the "Equity Award Conversion Ratio").

F5: This option provided for vesting as to 108,839 shares on December 15, 2017 and vesting as to 9,071 shares per month thereafter.

F6: This vested option was cancelled at the effective time of the Merger in exchange for a cash payment equal to the per-share merger consideration, less the exercise price of the option.

F7: Pursuant to the terms of the Merger Agreement, each option to purchase Company common stock (each, a "Company Option") then outstanding and unexercised, other than any vested in-the-money Company Option, was assumed and converted into an option to purchase a number of shares of Parent common stock, on the same terms and subject to the same conditions as were applicable to such Company Option, equal to the product of (i) the total number of shares of Company common stock subject to such Company Option multiplied by (ii) the Equity Award Conversion Ratio, and with an exercise price equal to the quotient of (i) the exercise price of such Company Option divided by (ii) the Equity Award Conversion Ratio.

F8: This option provided for 25% vesting on June 20, 2015, and vesting thereafter in 36 equal monthly installments.

F9: This option provided for 25% vesting on December 24, 2015, and vesting thereafter in 36 equal monthly installments.

F10: This option provided for 25% vesting on December 17, 2016, and vesting thereafter in 36 equal monthly installments.

F11: This option provides for 25% vesting on December 22, 2017, and vesting thereafter in 36 equal monthly installments.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
June 29, 2026 Filed Jul 1, 2026 20:11 UTC	Autolus Therapeutics plc AUTL · Entity 1933	GrantShare Option (Right to Buy) · Derivative	47,500	$0.00 Strike: $1.61	$0.00	Disclosure SEC source: 0001730463-26-000097 · form4.xml · derivative · entry 2 BUTITTA CYNTHIA M · CIK 0001222082 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 47,500 Underlying: American Depositary Shares · 47,500 shares Expires 2036-06-29 F3 · derivative.exercise_date: Share options vest in twelve equal monthly installments commencing on July 29, 2026. Read SEC document
June 29, 2026 Filed Jul 1, 2026 20:11 UTC	Autolus Therapeutics plc AUTL · Entity 1933	GrantRestricted Share Units · Derivative	31,667	$0.00	$0.00	Disclosure SEC source: 0001730463-26-000097 · form4.xml · derivative · entry 1 BUTITTA CYNTHIA M · CIK 0001222082 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 31,667 Underlying: American Depositary Shares · 31,667 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit (RSU) represents a contingent right to receive one share of the Issuer's American Depositary Shares. Each American Depositary Share is convertible at any time at the option of the Reporting Person into one Ordinary Share. F2 · derivative.exercise_date: The RSUs vest in one installment on June 29, 2027. F2 · derivative.expiration_date: The RSUs vest in one installment on June 29, 2027. Read SEC document
June 22, 2026 Filed Jun 24, 2026 14:00 UTC	UroGen Pharma Ltd. URGN · Entity 4466	GrantRestricted Stock Unit · Derivative	8,000	$0.00	$0.00	Disclosure SEC source: 0001437749-26-021513 · rdgdoc.xml · derivative · entry 2 BUTITTA CYNTHIA M · CIK 0001222082 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,000 Underlying: Ordinary Shares · 8,000 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one ordinary share of the Issuer F3 · derivative.exercise_date: The shares underlying the RSUs will vest in equal quarterly installments over a period of one year, subject to the director's Continuous Service (as defined in the 2017 Equity Incentive Plan) through such vesting dates. F3 · derivative.expiration_date: The shares underlying the RSUs will vest in equal quarterly installments over a period of one year, subject to the director's Continuous Service (as defined in the 2017 Equity Incentive Plan) through such vesting dates. Read SEC document
June 22, 2026 Filed Jun 24, 2026 14:00 UTC	UroGen Pharma Ltd. URGN · Entity 4466	GrantStock Option (right ot buy) · Derivative	10,000	$0.00 Strike: $34.99	$0.00	Disclosure SEC source: 0001437749-26-021513 · rdgdoc.xml · derivative · entry 1 BUTITTA CYNTHIA M · CIK 0001222082 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,000 Underlying: Ordinary Shares · 10,000 shares Expires 2036-06-22 F1 · derivative.exercise_date: The shares underlying the stock option will vest in equal quarterly installments over a period of one year, subject to the director's Continuous Service (as defined in the 2017 Equity Incentive Plan) through such vesting dates. Read SEC document
June 18, 2026 Filed Jun 23, 2026 21:29 UTC	Olema Pharmaceuticals, Inc. OLMA · Entity 613	GrantStock Option (right to buy) · Derivative	29,500	$0.00 Strike: $9.51	$0.00	Disclosure SEC source: 0001222082-26-000004 · form4-06232026_090608.xml · derivative · entry 1 BUTITTA CYNTHIA M · CIK 0001222082 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 29,500 Underlying: Common Stock · 29,500 shares Expires 2036-06-18 F1 · derivative.exercise_date: The shares subject to the option vest in a series of 12 successive equal monthly installments measured from June 18, 2026, subject to the Reporting Person's continuous service through each applicable vesting date. Such shares vest in full on the date of the Issuer's next annual meeting of stockholders if such stock option is not otherwise fully vested by such date, subject to the Reporting Person's continuous service through such vesting date. Read SEC document
November 26, 2025 Filed Dec 1, 2025 21:52 UTC	UroGen Pharma Ltd. URGN · Entity 4466	Exercise / conversionRestricted Stock Unit · Derivative	2,000	$0.00	$0.00	Disclosure SEC source: 0001437749-25-036565 · rdgdoc.xml · derivative · entry 2 BUTITTA CYNTHIA M · CIK 0001222082 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,000 Underlying: Ordinary Shares · 2,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one ordinary share of the Issuer F1 · derivative.exercise_date: Each restricted stock unit ("RSU") represents a contingent right to receive one ordinary share of the Issuer F1 · derivative.expiration_date: Each restricted stock unit ("RSU") represents a contingent right to receive one ordinary share of the Issuer Read SEC document
November 26, 2025 Filed Dec 1, 2025 21:52 UTC	UroGen Pharma Ltd. URGN · Entity 4466	Exercise / conversionordinary shares	2,000	Not disclosed	Not disclosed	Disclosure SEC source: 0001437749-25-036565 · rdgdoc.xml · nonDerivative · entry 1 BUTITTA CYNTHIA M · CIK 0001222082 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive one ordinary share of the Issuer Read SEC document
August 26, 2025 Filed Aug 27, 2025 20:37 UTC	UroGen Pharma Ltd. URGN · Entity 4466	GrantRestricted Stock Unit · Derivative	8,000	$0.00	$0.00	Disclosure SEC source: 0001437749-25-027879 · rdgdoc.xml · derivative · entry 2 BUTITTA CYNTHIA M · CIK 0001222082 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,000 Underlying: Ordinary Shares · 8,000 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one ordinary share of the Issuer F3 · derivative.exercise_date: The shares underlying the RSUs will vest in equal quarterly installments over a period of one year, subject to the director's Continuous Service (as defined in the 2017 Equity Incentive Plan) through such vesting dates. F3 · derivative.expiration_date: The shares underlying the RSUs will vest in equal quarterly installments over a period of one year, subject to the director's Continuous Service (as defined in the 2017 Equity Incentive Plan) through such vesting dates. Read SEC document
August 26, 2025 Filed Aug 27, 2025 20:37 UTC	UroGen Pharma Ltd. URGN · Entity 4466	GrantStock Option (right ot buy) · Derivative	10,000	$0.00 Strike: $19.50	$0.00	Disclosure SEC source: 0001437749-25-027879 · rdgdoc.xml · derivative · entry 1 BUTITTA CYNTHIA M · CIK 0001222082 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,000 Underlying: Ordinary Shares · 10,000 shares Expires 2035-08-26 F1 · derivative.exercise_date: The shares underlying the stock option will vest in equal quarterly installments over a period of one year, subject to the director's Continuous Service (as defined in the 2017 Equity Incentive Plan) through such vesting dates. Read SEC document
June 12, 2025 Filed Jun 16, 2025 22:23 UTC	Century Therapeutics, Inc. IPSC · Entity 5739	GrantStock Option (right to buy) · Derivative	44,000	$0.00 Strike: $0.60	$0.00	Disclosure SEC source: 0001062993-25-011783 · form4.xml · derivative · entry 1 BUTITTA CYNTHIA M · CIK 0001222082 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 44,000 Underlying: Common Stock · 44,000 shares Expires 2035-06-12 F1 · derivative.exercise_date: The option vests on the earlier of (a) June 12, 2026, or (b) the next annual meeting of stockholders, in each case subject to the Reporting Person's continued service through the applicable vesting date. Read SEC document
June 11, 2025 Filed Jun 13, 2025 21:00 UTC	Olema Pharmaceuticals, Inc. OLMA · Entity 613	GrantStock Option (right to buy) · Derivative	24,150	$0.00 Strike: $4.08	$0.00	Disclosure SEC source: 0001415889-25-017233 · form4-06132025_050612.xml · derivative · entry 1 BUTITTA CYNTHIA M · CIK 0001222082 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 24,150 Underlying: Common Stock · 24,150 shares Expires 2035-06-11 F1 · derivative.exercise_date: The shares subject to the option vest in a series of 12 successive equal monthly installments measured from June 11, 2025, subject to the Reporting Person's continuous service through each applicable vesting date. Such shares vest in full on the date of the Issuer's next annual meeting of stockholders if such stock option is not otherwise fully vested by such date, subject to the Reporting Person's continuous service through such vesting date. Read SEC document
August 06, 2024 Filed Aug 8, 2024 13:06 UTC	UroGen Pharma Ltd. URGN · Entity 4466	GrantStock Option (right ot buy) · Derivative	10,000	$0.00 Strike: $15.16	$0.00	Disclosure SEC source: 0001437749-24-025291 · rdgdoc.xml · derivative · entry 1 BUTITTA CYNTHIA M · CIK 0001222082 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,000 Underlying: Ordinary Shares · 10,000 shares Expires 2034-08-06 F1 · derivative.exercise_date: The shares underlying the stock option will vest in equal quarterly installments over a period of one year, subject to the director's Continuous Service (as defined in the 2017 Equity Incentive Plan) through such vesting dates. Read SEC document
June 20, 2024 Filed Jun 21, 2024 20:50 UTC	Century Therapeutics, Inc. IPSC · Entity 5739	GrantStock Option (right to buy) · Derivative	44,000	$0.00 Strike: $2.69	$0.00	Disclosure SEC source: 0001062993-24-012904 · form4.xml · derivative · entry 1 BUTITTA CYNTHIA M · CIK 0001222082 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 44,000 Underlying: Common Stock · 44,000 shares Expires 2034-06-20 F1 · derivative.exercise_date: The option vests on the earlier of (a) June 20, 2025, or (b) the next annual meeting of stockholders, in each case subject to the Reporting Person's continued service through the applicable vesting date. Read SEC document
June 14, 2024 Filed Jun 18, 2024 21:00 UTC	Olema Pharmaceuticals, Inc. OLMA · Entity 613	GrantStock Option (right to buy) · Derivative	23,000	$0.00 Strike: $12.36	$0.00	Disclosure SEC source: 0001415889-24-017441 · form4-06182024_050605.xml · derivative · entry 1 BUTITTA CYNTHIA M · CIK 0001222082 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,000 Underlying: Common Stock · 23,000 shares Expires 2034-06-14 F1 · derivative.exercise_date: The shares subject to the option vest in a series of 12 successive equal monthly installments measured from June 14, 2024, subject to the Reporting Person's continuous service through each applicable vesting date. Such shares vest in full on the date of the Issuer's next annual meeting of stockholders if such stock option is not otherwise fully vested by such date, subject to the Reporting Person's continuous service through such vesting date. Read SEC document
September 07, 2023 Filed Sep 8, 2023 19:43 UTC	UroGen Pharma Ltd. URGN · Entity 4466	GrantStock Option (right ot buy) · Derivative	10,000	$0.00 Strike: $16.85	$0.00	Disclosure SEC source: 0001437749-23-025485 · rdgdoc.xml · derivative · entry 1 BUTITTA CYNTHIA M · CIK 0001222082 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,000 Underlying: Ordinary Shares · 10,000 shares Expires 2033-09-07 F1 · derivative.exercise_date: The shares underlying the stock option will vest in equal quarterly installments over a period of one year. Read SEC document
June 27, 2023 Filed Jun 29, 2023 20:20 UTC	Century Therapeutics, Inc. IPSC · Entity 5739	GrantStock Option (right to buy) · Derivative	44,000	$0.00 Strike: $3.19	$0.00	Disclosure SEC source: 0001062993-23-014169 · form4.xml · derivative · entry 1 BUTITTA CYNTHIA M · CIK 0001222082 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 44,000 Underlying: Common Stock · 44,000 shares Expires 2024-06-27 F1 · derivative.exercise_date: The option vests on the earlier of (a) June 27, 2024, or (b) the next annual meeting of stockholders, in each case subject to the Reporting Person's continued service through the applicable vesting date. Read SEC document
June 16, 2023 Filed Jun 21, 2023 21:00 UTC	Olema Pharmaceuticals, Inc. OLMA · Entity 613	GrantStock Option (right to buy) · Derivative	21,520	$0.00 Strike: $7.84	$0.00	Disclosure SEC source: 0001415889-23-010101 · form4-06212023_050603.xml · derivative · entry 1 BUTITTA CYNTHIA M · CIK 0001222082 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,520 Underlying: Common Stock · 21,520 shares Expires 2033-06-15 F1 · derivative.exercise_date: The shares subject to the option vest in a series of 12 successive equal monthly installments measured from June 16, 2023, subject to the Reporting Person's continuous service through each applicable vesting date. Such shares vest in full on the date of the Issuer's next annual meeting of stockholders if such stock option is not otherwise fully vested by such date, subject to the Reporting Person's continuous service through such vesting date. Read SEC document
June 17, 2022 Filed Jun 27, 2022 21:12 UTC Amendment	Olema Pharmaceuticals, Inc. OLMA · Entity 613	GrantStock Option (right to buy) · Derivative	21,520	$0.00 Strike: $3.61	$0.00	Disclosure SEC source: 0001415889-22-006962 · form4a-06272022_020617.xml · derivative · entry 1 BUTITTA CYNTHIA M · CIK 0001222082 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,520 Underlying: Common Stock · 21,520 shares Expires 2032-06-16 F1 · derivative.exercise_price: This amendment is being filed solely for the purpose of correcting the transaction date and exercise price. The correct transaction date is "June 17, 2022" and the correct exercise price is "$3.61" as shown herein. F1 · date: This amendment is being filed solely for the purpose of correcting the transaction date and exercise price. The correct transaction date is "June 17, 2022" and the correct exercise price is "$3.61" as shown herein. F2 · derivative.exercise_date: The shares subject to the option vest in a series of 12 successive equal monthly installments measured from June 17, 2022, subject to the Reporting Person's continuous service through each applicable vesting date. Such shares vest in full on the date of the Issuer's next annual meeting of stockholders if such stock option is not otherwise fully vested by such date, subject to the Reporting Person's continuous service through such vesting date. Read SEC document
June 16, 2022 Filed Jun 17, 2022 23:25 UTC	Olema Pharmaceuticals, Inc. OLMA · Entity 613	GrantStock Option (right to buy) · Derivative	21,520	$0.00 Strike: $3.43	$0.00	Disclosure SEC source: 0001415889-22-006781 · form4-06172022_040613.xml · derivative · entry 1 BUTITTA CYNTHIA M · CIK 0001222082 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,520 Underlying: Common Stock · 21,520 shares Expires 2032-06-15 F1 · derivative.exercise_date: The shares subject to the option vest in a series of 12 successive equal monthly installments measured from June 16, 2022, subject to the Reporting Person's continuous service through each applicable vesting date. Such shares vest in full on the date of the Issuer's next annual meeting of stockholders if such stock option is not otherwise fully vested by such date, subject to the Reporting Person's continuous service through such vesting date. Read SEC document
June 09, 2022 Filed Jun 10, 2022 20:23 UTC	Century Therapeutics, Inc. IPSC · Entity 5739	GrantStock Option (right to buy) · Derivative	19,872	$0.00 Strike: $8.56	$0.00	Disclosure SEC source: 0001062993-22-014659 · form4.xml · derivative · entry 1 BUTITTA CYNTHIA M · CIK 0001222082 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,872 Underlying: Common Stock · 19,872 shares Expires 2032-06-09 F1 · derivative.exercise_date: The option vests on the earlier of (a) June 9, 2023, or (b) the next annual meeting of stockholders, in each case subject to the Reporting Person's continued service through the applicable vesting date. Read SEC document
June 08, 2022 Filed Jun 10, 2022 19:37 UTC	UroGen Pharma Ltd. URGN · Entity 4466	GrantStock Option (right to buy) · Derivative	10,000	$0.00 Strike: $7.06	$0.00	Disclosure SEC source: 0001437749-22-014773 · rdgdoc.xml · derivative · entry 1 BUTITTA CYNTHIA M · CIK 0001222082 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Ordinary Shares · 10,000 shares Expires 2032-06-08 F1 · derivative.exercise_date: The shares underlying the stock option will vest in equal quarterly installments over a period of one year. Read SEC document
June 17, 2021 Filed Jun 21, 2021 20:32 UTC	Century Therapeutics, Inc. IPSC · Entity 5739	GrantOption (right to buy) · Derivative	19,872	$0.00 Strike: $20.00	$0.00	Disclosure SEC source: 0001192482-21-000559 · edgar.xml · derivative · entry 1 BUTITTA CYNTHIA M · CIK 0001222082 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,872 Underlying: Common Stock · 19,872 shares Expires 2031-06-17 F1 · derivative.exercise_date: The option vests on the earlier of (a) June 17, 2022 or (b) the next annual meeting of stockholders, subject to the Reporting Person's continued service through the applicable vesting date. Read SEC document
June 09, 2021 Filed Jun 10, 2021 22:36 UTC	Olema Pharmaceuticals, Inc. OLMA · Entity 613	GrantStock Option (right to buy) · Derivative	21,520	$0.00 Strike: $27.66	$0.00	Disclosure SEC source: 0001415889-21-002925 · form4-06102021_030639.xml · derivative · entry 1 BUTITTA CYNTHIA M · CIK 0001222082 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,520 Underlying: Common Stock · 21,520 shares Expires 2031-06-08 F1 · derivative.exercise_date: The shares subject to the option vest in a series of 12 successive equal monthly installments measured from June 9, 2021, subject to the Reporting Person's continuous service through each applicable vesting date. Such shares vest in full on the date of the Issuer's next annual meeting of stockholders if such stock option is not otherwise fully vested by such date, subject to the Reporting Person's continuous service through such vesting date. Read SEC document
June 07, 2021 Filed Jun 9, 2021 17:44 UTC	UroGen Pharma Ltd. URGN · Entity 4466	GrantStock Option (right to buy) · Derivative	10,000	$0.00 Strike: $17.98	$0.00	Disclosure SEC source: 0001209191-21-039135 · doc4.xml · derivative · entry 1 BUTITTA CYNTHIA M · CIK 0001222082 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2031-06-06 F1 · derivative.exercise_date: The shares underlying the stock option will vest in equal quarterly installments over a period of one year. Read SEC document
November 18, 2020 Filed Nov 19, 2020 23:42 UTC	Olema Pharmaceuticals, Inc. OLMA · Entity 613	GrantStock Option (Right to Buy) · Derivative	21,520	$0.00 Strike: $19.00	$0.00	Disclosure SEC source: 0001209191-20-059510 · doc4.xml · derivative · entry 4 BUTITTA CYNTHIA M · CIK 0001222082 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,520 Underlying: Common Stock · 21,520 shares Expires 2030-11-17 F2 · derivative.exercise_date: The shares subject to the option vest in a series of 12 successive equal monthy installments measured from June 1, 2020, subject to the Reporting Person's continuous service through each applicable vesting date. Such shares vest in full on the date of the Issuer's next annual meeting of stockholders if such stock option is not otherwise fully vested by such date, subject to the Reporting Person's continuous service through such vesting date. Read SEC document
September 16, 2020 Filed Nov 19, 2020 23:42 UTC	Olema Pharmaceuticals, Inc. OLMA · Entity 613	Exercise / conversionStock Option (Right to Buy) · Derivative	83,876	$0.00 Strike: $4.41	$0.00	Disclosure SEC source: 0001209191-20-059510 · doc4.xml · derivative · entry 3 BUTITTA CYNTHIA M · CIK 0001222082 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 83,876 shares Expires 2030-08-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The shares subject to the option vest in a series of 36 successive equal monthly installments measured from August 12, 2020, subject to the Reporting Person's continuous service through each applicable vesting date. The stock option is early exercisable. Read SEC document
September 16, 2020 Filed Nov 19, 2020 23:42 UTC	Olema Pharmaceuticals, Inc. OLMA · Entity 613	Exercise / conversionCommon Stock	83,876	$4.41	$369,557.66	Disclosure SEC source: 0001209191-20-059510 · doc4.xml · nonDerivative · entry 1 BUTITTA CYNTHIA M · CIK 0001222082 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 83,876 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
August 12, 2020 Filed Nov 19, 2020 23:42 UTC	Olema Pharmaceuticals, Inc. OLMA · Entity 613	GrantStock Option (Right to Buy) · Derivative	83,876	$0.00 Strike: $4.41	$0.00	Disclosure SEC source: 0001209191-20-059510 · doc4.xml · derivative · entry 2 BUTITTA CYNTHIA M · CIK 0001222082 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 83,876 Underlying: Common Stock · 83,876 shares Expires 2030-08-11 F1 · derivative.exercise_date: The shares subject to the option vest in a series of 36 successive equal monthly installments measured from August 12, 2020, subject to the Reporting Person's continuous service through each applicable vesting date. The stock option is early exercisable. Read SEC document
June 08, 2020 Filed Jun 10, 2020 22:36 UTC	UroGen Pharma Ltd. URGN · Entity 4466	GrantStock Option (right to buy) · Derivative	10,000	$0.00 Strike: $28.24	$0.00	Disclosure SEC source: 0001209191-20-035677 · doc4.xml · derivative · entry 1 BUTITTA CYNTHIA M · CIK 0001222082 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Ordinary Shares · 10,000 shares Expires 2030-06-07 F1 · derivative.exercise_date: The shares underlying the stock option will vest in equal quarterly installments over a period of one year. Read SEC document
June 03, 2019 Filed Jun 5, 2019 20:58 UTC	UroGen Pharma Ltd. URGN · Entity 4466	GrantStock Option (Right to Buy) · Derivative	10,000	$0.00 Strike: $34.83	$0.00	Disclosure SEC source: 0001209191-19-034788 · doc4.xml · derivative · entry 1 BUTITTA CYNTHIA M · CIK 0001222082 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Ordinary Shares · 10,000 shares Expires 2029-06-02 F1 · derivative.exercise_date: The shares underlying the stock option will vest in equal quarterly installments over a period of two years. Read SEC document
October 03, 2017 Filed Oct 6, 2017 00:11 UTC	Kite Pharma, Inc. KITE · Entity 172664	Disposition to issuerEmployee Stock Option (Right to Buy) · Derivative	90,600	Not disclosed Strike: $46.09	Not disclosed	Disclosure SEC source: 0001209191-17-056216 · doc4.xml · derivative · entry 11 BUTITTA CYNTHIA M · CIK 0001222082 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 90,600 shares Expires 2026-12-21 F1 · date: On August 27, 2017, Kite Pharma, Inc., a Delaware corporation (the "Company"), entered into an Agreement and Plan of Merger (the "Merger Agreement") with Gilead Sciences, Inc., a Delaware corporation ("Parent"), and Dodgers Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Purchaser"). On October 3, 2017, Purchaser merged with and into the Company pursuant to Section 251(h) of the General Corporation Law of the State of Delaware, with the Company being the surviving corporation (the "Merger") and becoming a wholly-owned subsidiary of Parent. F7 · price: Pursuant to the terms of the Merger Agreement, each option to purchase Company common stock (each, a "Company Option") then outstanding and unexercised, other than any vested in-the-money Company Option, was assumed and converted into an option to purchase a number of shares of Parent common stock, on the same terms and subject to the same conditions as were applicable to such Company Option, equal to the product of (i) the total number of shares of Company common stock subject to such Company Option multiplied by (ii) the Equity Award Conversion Ratio, and with an exercise price equal to the quotient of (i) the exercise price of such Company Option divided by (ii) the Equity Award Conversion Ratio. F11 · derivative.exercise_date: This option provides for 25% vesting on December 22, 2017, and vesting thereafter in 36 equal monthly installments. Read SEC document
October 03, 2017 Filed Oct 6, 2017 00:11 UTC	Kite Pharma, Inc. KITE · Entity 172664	Disposition to issuerEmployee Stock Option (Right to Buy) · Derivative	37,181	Not disclosed Strike: $63.87	Not disclosed	Disclosure SEC source: 0001209191-17-056216 · doc4.xml · derivative · entry 10 BUTITTA CYNTHIA M · CIK 0001222082 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 37,181 shares Expires 2025-12-16 F1 · date: On August 27, 2017, Kite Pharma, Inc., a Delaware corporation (the "Company"), entered into an Agreement and Plan of Merger (the "Merger Agreement") with Gilead Sciences, Inc., a Delaware corporation ("Parent"), and Dodgers Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Purchaser"). On October 3, 2017, Purchaser merged with and into the Company pursuant to Section 251(h) of the General Corporation Law of the State of Delaware, with the Company being the surviving corporation (the "Merger") and becoming a wholly-owned subsidiary of Parent. F7 · price: Pursuant to the terms of the Merger Agreement, each option to purchase Company common stock (each, a "Company Option") then outstanding and unexercised, other than any vested in-the-money Company Option, was assumed and converted into an option to purchase a number of shares of Parent common stock, on the same terms and subject to the same conditions as were applicable to such Company Option, equal to the product of (i) the total number of shares of Company common stock subject to such Company Option multiplied by (ii) the Equity Award Conversion Ratio, and with an exercise price equal to the quotient of (i) the exercise price of such Company Option divided by (ii) the Equity Award Conversion Ratio. F10 · derivative.exercise_date: This option provided for 25% vesting on December 17, 2016, and vesting thereafter in 36 equal monthly installments. Read SEC document
October 03, 2017 Filed Oct 6, 2017 00:11 UTC	Kite Pharma, Inc. KITE · Entity 172664	Disposition to issuerEmployee Stock Option (Right to Buy) · Derivative	28,919	$116.13 Strike: $63.87	$3,358,363.47	Disclosure SEC source: 0001209191-17-056216 · doc4.xml · derivative · entry 9 BUTITTA CYNTHIA M · CIK 0001222082 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 28,919 shares Expires 2025-12-16 F1 · date: On August 27, 2017, Kite Pharma, Inc., a Delaware corporation (the "Company"), entered into an Agreement and Plan of Merger (the "Merger Agreement") with Gilead Sciences, Inc., a Delaware corporation ("Parent"), and Dodgers Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Purchaser"). On October 3, 2017, Purchaser merged with and into the Company pursuant to Section 251(h) of the General Corporation Law of the State of Delaware, with the Company being the surviving corporation (the "Merger") and becoming a wholly-owned subsidiary of Parent. F6 · price: This vested option was cancelled at the effective time of the Merger in exchange for a cash payment equal to the per-share merger consideration, less the exercise price of the option. F10 · derivative.exercise_date: This option provided for 25% vesting on December 17, 2016, and vesting thereafter in 36 equal monthly installments. Read SEC document
October 03, 2017 Filed Oct 6, 2017 00:11 UTC	Kite Pharma, Inc. KITE · Entity 172664	Disposition to issuerEmployee Stock Option (Right to Buy) · Derivative	23,437	Not disclosed Strike: $51.96	Not disclosed	Disclosure SEC source: 0001209191-17-056216 · doc4.xml · derivative · entry 8 BUTITTA CYNTHIA M · CIK 0001222082 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 23,437 shares Expires 2024-12-23 F1 · date: On August 27, 2017, Kite Pharma, Inc., a Delaware corporation (the "Company"), entered into an Agreement and Plan of Merger (the "Merger Agreement") with Gilead Sciences, Inc., a Delaware corporation ("Parent"), and Dodgers Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Purchaser"). On October 3, 2017, Purchaser merged with and into the Company pursuant to Section 251(h) of the General Corporation Law of the State of Delaware, with the Company being the surviving corporation (the "Merger") and becoming a wholly-owned subsidiary of Parent. F7 · price: Pursuant to the terms of the Merger Agreement, each option to purchase Company common stock (each, a "Company Option") then outstanding and unexercised, other than any vested in-the-money Company Option, was assumed and converted into an option to purchase a number of shares of Parent common stock, on the same terms and subject to the same conditions as were applicable to such Company Option, equal to the product of (i) the total number of shares of Company common stock subject to such Company Option multiplied by (ii) the Equity Award Conversion Ratio, and with an exercise price equal to the quotient of (i) the exercise price of such Company Option divided by (ii) the Equity Award Conversion Ratio. F9 · derivative.exercise_date: This option provided for 25% vesting on December 24, 2015, and vesting thereafter in 36 equal monthly installments. Read SEC document
October 03, 2017 Filed Oct 6, 2017 00:11 UTC	Kite Pharma, Inc. KITE · Entity 172664	Disposition to issuerEmployee Stock Option (Right to Buy) · Derivative	51,563	$128.04 Strike: $51.96	$6,602,126.52	Disclosure SEC source: 0001209191-17-056216 · doc4.xml · derivative · entry 7 BUTITTA CYNTHIA M · CIK 0001222082 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 51,563 shares Expires 2024-12-23 F1 · date: On August 27, 2017, Kite Pharma, Inc., a Delaware corporation (the "Company"), entered into an Agreement and Plan of Merger (the "Merger Agreement") with Gilead Sciences, Inc., a Delaware corporation ("Parent"), and Dodgers Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Purchaser"). On October 3, 2017, Purchaser merged with and into the Company pursuant to Section 251(h) of the General Corporation Law of the State of Delaware, with the Company being the surviving corporation (the "Merger") and becoming a wholly-owned subsidiary of Parent. F6 · price: This vested option was cancelled at the effective time of the Merger in exchange for a cash payment equal to the per-share merger consideration, less the exercise price of the option. F9 · derivative.exercise_date: This option provided for 25% vesting on December 24, 2015, and vesting thereafter in 36 equal monthly installments. Read SEC document
October 03, 2017 Filed Oct 6, 2017 00:11 UTC	Kite Pharma, Inc. KITE · Entity 172664	Disposition to issuerEmployee Stock Option (Right to Buy) · Derivative	28,034	Not disclosed Strike: $17.00	Not disclosed	Disclosure SEC source: 0001209191-17-056216 · doc4.xml · derivative · entry 6 BUTITTA CYNTHIA M · CIK 0001222082 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 28,034 shares Expires 2024-06-19 F1 · date: On August 27, 2017, Kite Pharma, Inc., a Delaware corporation (the "Company"), entered into an Agreement and Plan of Merger (the "Merger Agreement") with Gilead Sciences, Inc., a Delaware corporation ("Parent"), and Dodgers Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Purchaser"). On October 3, 2017, Purchaser merged with and into the Company pursuant to Section 251(h) of the General Corporation Law of the State of Delaware, with the Company being the surviving corporation (the "Merger") and becoming a wholly-owned subsidiary of Parent. F7 · price: Pursuant to the terms of the Merger Agreement, each option to purchase Company common stock (each, a "Company Option") then outstanding and unexercised, other than any vested in-the-money Company Option, was assumed and converted into an option to purchase a number of shares of Parent common stock, on the same terms and subject to the same conditions as were applicable to such Company Option, equal to the product of (i) the total number of shares of Company common stock subject to such Company Option multiplied by (ii) the Equity Award Conversion Ratio, and with an exercise price equal to the quotient of (i) the exercise price of such Company Option divided by (ii) the Equity Award Conversion Ratio. F8 · derivative.exercise_date: This option provided for 25% vesting on June 20, 2015, and vesting thereafter in 36 equal monthly installments. Read SEC document
October 03, 2017 Filed Oct 6, 2017 00:11 UTC	Kite Pharma, Inc. KITE · Entity 172664	Disposition to issuerEmployee Stock Option (Right to Buy) · Derivative	121,477	$163.00 Strike: $17.00	$19,800,751.00	Disclosure SEC source: 0001209191-17-056216 · doc4.xml · derivative · entry 5 BUTITTA CYNTHIA M · CIK 0001222082 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 121,477 shares Expires 2024-06-19 F1 · date: On August 27, 2017, Kite Pharma, Inc., a Delaware corporation (the "Company"), entered into an Agreement and Plan of Merger (the "Merger Agreement") with Gilead Sciences, Inc., a Delaware corporation ("Parent"), and Dodgers Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Purchaser"). On October 3, 2017, Purchaser merged with and into the Company pursuant to Section 251(h) of the General Corporation Law of the State of Delaware, with the Company being the surviving corporation (the "Merger") and becoming a wholly-owned subsidiary of Parent. F6 · price: This vested option was cancelled at the effective time of the Merger in exchange for a cash payment equal to the per-share merger consideration, less the exercise price of the option. F8 · derivative.exercise_date: This option provided for 25% vesting on June 20, 2015, and vesting thereafter in 36 equal monthly installments. Read SEC document
October 03, 2017 Filed Oct 6, 2017 00:11 UTC	Kite Pharma, Inc. KITE · Entity 172664	Disposition to issuerEmployee Stock Option (Right to Buy) · Derivative	36,284	Not disclosed Strike: $1.35	Not disclosed	Disclosure SEC source: 0001209191-17-056216 · doc4.xml · derivative · entry 4 BUTITTA CYNTHIA M · CIK 0001222082 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 36,284 shares Expires 2024-03-24 F1 · date: On August 27, 2017, Kite Pharma, Inc., a Delaware corporation (the "Company"), entered into an Agreement and Plan of Merger (the "Merger Agreement") with Gilead Sciences, Inc., a Delaware corporation ("Parent"), and Dodgers Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Purchaser"). On October 3, 2017, Purchaser merged with and into the Company pursuant to Section 251(h) of the General Corporation Law of the State of Delaware, with the Company being the surviving corporation (the "Merger") and becoming a wholly-owned subsidiary of Parent. F7 · price: Pursuant to the terms of the Merger Agreement, each option to purchase Company common stock (each, a "Company Option") then outstanding and unexercised, other than any vested in-the-money Company Option, was assumed and converted into an option to purchase a number of shares of Parent common stock, on the same terms and subject to the same conditions as were applicable to such Company Option, equal to the product of (i) the total number of shares of Company common stock subject to such Company Option multiplied by (ii) the Equity Award Conversion Ratio, and with an exercise price equal to the quotient of (i) the exercise price of such Company Option divided by (ii) the Equity Award Conversion Ratio. F5 · derivative.exercise_date: This option provided for vesting as to 108,839 shares on December 15, 2017 and vesting as to 9,071 shares per month thereafter. Read SEC document
October 03, 2017 Filed Oct 6, 2017 00:11 UTC	Kite Pharma, Inc. KITE · Entity 172664	Disposition to issuerEmployee Stock Option (Right to Buy) · Derivative	44,110	$178.65 Strike: $1.35	$7,880,251.50	Disclosure SEC source: 0001209191-17-056216 · doc4.xml · derivative · entry 3 BUTITTA CYNTHIA M · CIK 0001222082 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 44,110 shares Expires 2024-03-24 F1 · date: On August 27, 2017, Kite Pharma, Inc., a Delaware corporation (the "Company"), entered into an Agreement and Plan of Merger (the "Merger Agreement") with Gilead Sciences, Inc., a Delaware corporation ("Parent"), and Dodgers Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Purchaser"). On October 3, 2017, Purchaser merged with and into the Company pursuant to Section 251(h) of the General Corporation Law of the State of Delaware, with the Company being the surviving corporation (the "Merger") and becoming a wholly-owned subsidiary of Parent. F6 · price: This vested option was cancelled at the effective time of the Merger in exchange for a cash payment equal to the per-share merger consideration, less the exercise price of the option. F5 · derivative.exercise_date: This option provided for vesting as to 108,839 shares on December 15, 2017 and vesting as to 9,071 shares per month thereafter. Read SEC document
October 03, 2017 Filed Oct 6, 2017 00:11 UTC	Kite Pharma, Inc. KITE · Entity 172664	Disposition to issuerCommon Stock	93,667	Not disclosed	Not disclosed	Disclosure SEC source: 0001209191-17-056216 · doc4.xml · nonDerivative · entry 2 BUTITTA CYNTHIA M · CIK 0001222082 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · date: On August 27, 2017, Kite Pharma, Inc., a Delaware corporation (the "Company"), entered into an Agreement and Plan of Merger (the "Merger Agreement") with Gilead Sciences, Inc., a Delaware corporation ("Parent"), and Dodgers Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Purchaser"). On October 3, 2017, Purchaser merged with and into the Company pursuant to Section 251(h) of the General Corporation Law of the State of Delaware, with the Company being the surviving corporation (the "Merger") and becoming a wholly-owned subsidiary of Parent. F2 · date: Pursuant to the terms of the Merger Agreement and the Offer (as defined in the Merger Agreement), each share of Company common stock held by the Reporting Person, other than the shares described in Notes 3 and 4 below, was converted into the right to receive an amount in cash equal to $180.00 (the "per-share merger consideration"), without interest and subject to any required withholding of taxes. F3 · shares: Includes 38,675 shares of Company common stock underlying restricted stock units with respect to Company common stock, including all time-vesting and all performance-vesting restricted stock units (each a "Company Restricted Stock Unit"), held by the Reporting Person. F4 · shares: Pursuant to the terms of the Merger Agreement, each Company Restricted Stock Unit was assumed and converted into a restricted stock unit denominated in shares of Parent common stock, on the same terms and conditions as were then applicable under such Company Restricted Stock Unit (including applicable performance vesting conditions), and relating to a number of shares of Parent common stock equal to the product of (i) the total number of shares of Company common stock subject to such Company Restricted Stock Unit multiplied by (ii) the quotient of (A) $180.00 divided by (B) the volume-weighted average closing sale price of a share of Parent common stock for the fifteen full consecutive trading days ending on and including September 28, 2017 ($83.12) (such quotient, the "Equity Award Conversion Ratio"). F2 · price: Pursuant to the terms of the Merger Agreement and the Offer (as defined in the Merger Agreement), each share of Company common stock held by the Reporting Person, other than the shares described in Notes 3 and 4 below, was converted into the right to receive an amount in cash equal to $180.00 (the "per-share merger consideration"), without interest and subject to any required withholding of taxes. F4 · price: Pursuant to the terms of the Merger Agreement, each Company Restricted Stock Unit was assumed and converted into a restricted stock unit denominated in shares of Parent common stock, on the same terms and conditions as were then applicable under such Company Restricted Stock Unit (including applicable performance vesting conditions), and relating to a number of shares of Parent common stock equal to the product of (i) the total number of shares of Company common stock subject to such Company Restricted Stock Unit multiplied by (ii) the quotient of (A) $180.00 divided by (B) the volume-weighted average closing sale price of a share of Parent common stock for the fifteen full consecutive trading days ending on and including September 28, 2017 ($83.12) (such quotient, the "Equity Award Conversion Ratio"). Read SEC document
September 25, 2017 Filed Sep 28, 2017 01:38 UTC	Kite Pharma, Inc. KITE · Entity 172664	SaleCommon Stock	4,228	$179.66	$759,618.97	Disclosure SEC source: 0001209191-17-054194 · doc4.xml · nonDerivative · entry 2 BUTITTA CYNTHIA M · CIK 0001222082 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 121,567 F1 · kind: The shares were sold to cover the tax obligation that occurred upon the vesting of an RSU. Read SEC document
September 25, 2017 Filed Sep 28, 2017 01:38 UTC	Kite Pharma, Inc. KITE · Entity 172664	GrantCommon Stock	8,000	$0.00	$0.00	Disclosure SEC source: 0001209191-17-054194 · doc4.xml · nonDerivative · entry 1 BUTITTA CYNTHIA M · CIK 0001222082 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 125,795 Read SEC document
September 21, 2017 Filed Oct 6, 2017 00:11 UTC	Kite Pharma, Inc. KITE · Entity 172664	GiftCommon Stock	27,900	$0.00	$0.00	Disclosure SEC source: 0001209191-17-056216 · doc4.xml · nonDerivative · entry 1 BUTITTA CYNTHIA M · CIK 0001222082 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 93,667 Read SEC document
August 10, 2017 Filed Aug 14, 2017 21:03 UTC	Kite Pharma, Inc. KITE · Entity 172664	Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative	15,000	$0.00 Strike: $1.35	$0.00	Disclosure SEC source: 0001209191-17-048785 · doc4.xml · derivative · entry 4 BUTITTA CYNTHIA M · CIK 0001222082 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 80,394 Underlying: Common Stock · 15,000 shares Expires 2024-03-25 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: 108,839 of the 435,394 shares originally subject to the stock option vested and became exercisable on December 15, 2014, and 9,071 shares vest monthly thereafter. Read SEC document
August 10, 2017 Filed Aug 14, 2017 21:03 UTC	Kite Pharma, Inc. KITE · Entity 172664	SaleCommon Stock	5,800	$121.03	$701,974.00	Disclosure SEC source: 0001209191-17-048785 · doc4.xml · nonDerivative · entry 3 BUTITTA CYNTHIA M · CIK 0001222082 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 117,795 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 9, 2017. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $120.82 to $141.42, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. Read SEC document
August 10, 2017 Filed Aug 14, 2017 21:03 UTC	Kite Pharma, Inc. KITE · Entity 172664	SaleCommon Stock	9,200	$120.52	$1,108,784.00	Disclosure SEC source: 0001209191-17-048785 · doc4.xml · nonDerivative · entry 2 BUTITTA CYNTHIA M · CIK 0001222082 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 123,595 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 9, 2017. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $119.79 to $120.72, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. Read SEC document
August 10, 2017 Filed Aug 14, 2017 21:03 UTC	Kite Pharma, Inc. KITE · Entity 172664	Exercise / conversionCommon Stock	15,000	$1.35	$20,250.00	Disclosure SEC source: 0001209191-17-048785 · doc4.xml · nonDerivative · entry 1 BUTITTA CYNTHIA M · CIK 0001222082 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 132,795 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
July 10, 2017 Filed Jul 11, 2017 21:36 UTC	Kite Pharma, Inc. KITE · Entity 172664	Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative	15,000	$0.00 Strike: $1.35	$0.00	Disclosure SEC source: 0001209191-17-044804 · doc4.xml · derivative · entry 6 BUTITTA CYNTHIA M · CIK 0001222082 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 95,394 Underlying: Common Stock · 15,000 shares Expires 2024-03-25 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: 108,839 of the 435,394 shares originally subject to the stock option vested and became exercisable on December 15, 2014, and 9,071 shares vest monthly thereafter. Read SEC document
July 10, 2017 Filed Jul 11, 2017 21:36 UTC	Kite Pharma, Inc. KITE · Entity 172664	SaleCommon Stock	5,000	$105.50	$527,500.00	Disclosure SEC source: 0001209191-17-044804 · doc4.xml · nonDerivative · entry 5 BUTITTA CYNTHIA M · CIK 0001222082 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 117,795 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 9, 2017. Read SEC document
July 10, 2017 Filed Jul 11, 2017 21:36 UTC	Kite Pharma, Inc. KITE · Entity 172664	SaleCommon Stock	1,100	$102.81	$113,091.00	Disclosure SEC source: 0001209191-17-044804 · doc4.xml · nonDerivative · entry 4 BUTITTA CYNTHIA M · CIK 0001222082 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 122,795 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 9, 2017. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $102.67 to $103.09, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.